A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514775-17-00

Acronym

19-00153

Enrollment

Registered

2024-08-22

Start date

2021-02-10

Completion date

Unknown

Last updated

2024-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant B-cell lymphoma

Brief summary

ORR of the regimen within the first 8 treatment cycles

Detailed description

ORR (Cheson 2007-criteria), Progression free survival (Lugano), Overall survival, CR-Rate (Lugano), Best response (Lugano), Quality of Life measured with EORTC QLQ C30 and NHL-HG29 (global QoL, physical functioning, fatigue), ORR in separate GCB vs. non GCB-analysis is planned, Safety Endpoints: Safety and tolerability as measured by rate of AE, SAE compared between Arm A and B

Interventions

DRUGRITUXIMAB

DRUGOXALIPLATIN

DRUGGEMCITABINE

DRUGMINJUVI 200 mg powder for concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
ORR (Cheson 2007-criteria), Progression free survival (Lugano), Overall survival, CR-Rate (Lugano), Best response (Lugano), Quality of Life measured with EORTC QLQ C30 and NHL-HG29 (global QoL, physical functioning, fatigue), ORR in separate GCB vs. non GCB-analysis is planned, Safety Endpoints: Safety and tolerability as measured by rate of AE, SAE compared between Arm A and B	—

Primary

Measure	Time frame
ORR of the regimen within the first 8 treatment cycles	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026